WO1991017427A1 - Method for determining a specific ligand in a fluid sample with the aid of an evanescent field, and also a component of the requisite measuring equipment suitable for this purpose - Google Patents
Method for determining a specific ligand in a fluid sample with the aid of an evanescent field, and also a component of the requisite measuring equipment suitable for this purpose Download PDFInfo
- Publication number
- WO1991017427A1 WO1991017427A1 PCT/NL1991/000073 NL9100073W WO9117427A1 WO 1991017427 A1 WO1991017427 A1 WO 1991017427A1 NL 9100073 W NL9100073 W NL 9100073W WO 9117427 A1 WO9117427 A1 WO 9117427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ligand
- optical element
- particle form
- supports
- binding partners
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/55—Specular reflectivity
- G01N21/552—Attenuated total reflection
- G01N21/553—Attenuated total reflection and using surface plasmons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
Definitions
- the invention relates to a method for determining a ligand in a fluid sample by bringing the sample into contact with a surface of an optical element which is capable of generating an evanescent field and which surface is provided with a specific binding partner for the ligand to be determined; irradiating the optical element with light of a wavelength suitable for production of the evanescent field; and analysing the reflected light in order to determine the possibly modified evanescent field characteristics of the optical element as a consequence of the formation of a complex between the ligand and the specific binding partner.
- SPR surface plasmon resonance
- a method of this type is disclosed in International Patent
- Fig. 1 (1) represents a shallow well in a clear plastic material, the flat base (2) of which is provided at the surface with a diffraction grating (3).
- the upper surface of the grating (3) is covered with a semi-reflecting material or a metal film, such as, for example, of silver, aluminium, copper or gold.
- the grating is coated with a thin film of specific binding partners for the ligand to be determined.
- specific binding partners for the ligand for example, anti- gens can be used as ligand and antibodies for the particular antigen as specific binding partners (see Fig. 2) .
- the determination as such takes place in a housing (4) which is shown in Fig. 1 and which is provided with a laser light source (5) , from which laser light is directed at a suitable angle onto the underside of the base (2) in order to generate the "surface plasmon resonance" (SPR) effect in the grating (3) .
- the reflected light is captured via a light detector (6), which is also fitted in the housing (4), and the electrical signal originating from detector (6) is processed in a measuring apparatus (7) , which may or may not be fitted in the housing (4).
- the signal originating from detector (6) changes if the relevant ligand, which binds to the specific binding partners bound to the metal layer, is present in the sample (8) , which is placed in the well (1) .
- the aim indicated above can be achieved if, in the method described in the preamble, the sample is used in combination with a suspension of supports in particle form, which supports carry the ligand (competition assay; see Fig. 3a and in particular 3*>) •
- the aim according to the invention can also be achieved if, in the method described in the preamble, an optical element is used of which the surface located at the fluid/solid interface is provided with a multiplicity of supports in particle form, which supports contain binding partners specific for the ligand (see Fig. ).
- the abovementioned aim can likewise be achieved with the aid of an optical element of which the surface located at the fluid/ solid interface contains a multiplicity of specific binding partners which are provided with a "leaving agent" in the form of particles reversibly bound to said specific binding partners (see Fig. 5) •
- the term "leaving agent" is defined as a support in particle form which is provided with at least one ligand.
- the abovementioned aim can also be achieved with the aid of an optical element of which the surface located at the fluid/solid interface contains a multiplicity of binding partners specific for the ligand, some of which are provided with the ligand and some with the "leaving agent", in accordance with an equilibrium setting with a medium, which is advantageously circulated, in which the ligand and the "leaving agent" are present in a constant concentration, this equilibrium setting temporarily shifting after administration of a sample to be investigated and giving a corresponding change in the evanescent field (Fig. 6a) .
- An important advantage of this last-mentioned solution lies in the fact that in this way "continuous" measurements can be carried out using, for example, SPR measuring equipment (Fig.
- a membrane which is permeable to the ligand to be measured but impermeable to the "leaving agent” is preferably inserted between the optical element and the location at which the sample to be investigated is supplied (Fig. 7).
- the above ⁇ mentioned medium, which is advantageously circulated has to contain only the relevant ligand in a constant concentration since the "leaving agent" cannot escape from the space between the membrane and the surface of the optical element.
- a particular variant of the first-mentioned solution consists in the use of an optical element of which the surface located at the fluid/solid interface is provided with a multiplicity of supports in particle form which contain binding partners specific for the ligand, these specific binding partners also being provided with a "leaving agent" in the form of a particle reversibly bound to said specific binding partners (see Fig. 8) .
- solu ⁇ tions all relate to increasing the change in mass per unit surface area of the optical element, so that it is a matter of "unity of invention” .
- the optical element used in the method according to the invention consists of a plastic material or glass having a suitable refractive index, which is preferably coated with a metal layer of silver or gold, the support particles loaded with specific binding partners being applied to the metal layer.
- the thickness of the metal layer is usually 10-100 nm and can be applied in a known manner, such as by vapour deposition and the like.
- the optical element is usually in the form of a platelet of a specific thick ⁇ ness.
- optical fibres and planar light conductors can also be used as optical element.
- support particles can be used as supports in particle form within the framework of the invention.
- latex spheres which have a diameter in the range of, for example, 10-500 nm are used as support.
- suitable materials are, inter alia, (monodisperse) polystyrene latex, poly- methyl methacrylate latex or a silica latex.
- latices are Unisphere latex particles having a diameter of 0 nm (type 10) or 100 nm (type 11) (Brunschwig Chemie B.V., The Nether ⁇ lands) and "Polybead" polystyrene microspheres having a diameter of 50, 100 or 200 nm (Polysciences Corp., Niles/Illinois, USA).
- Metal sols sol particles
- gold sols, silver sols and the like can also be used as support in particle form. It is also possible to use combinations of particles, such as, for example, particles of different size, particles containing different functional groups, particles having different intrinsic refractive indices and also latex with a metal sol.
- the combination of a latex with a metal sol can provide extra sensitivity and specificity in connection with overlap of two evanescent fields, that is to say the evanescent field generated with the apparatus and the evanescent field generated by the metal particle.
- the "degree of coverage" of the surface of the optical element, which is provided with the loaded supports in particle form can vary greatly.
- the degree of coverage depends on the size of the support particles or on the type of specific binding partner, such as antibodies and DNA strands.
- the degree of coverage is 50-99•5 *•
- “degree of coverage” of the surface of the optical element by the (“spherical") supports in particle form is understood to mean the ratio of the sum of the sur ⁇ face area of the cross-section of the "spherical" supports multiplied by a factor of 100, divided by the total surface area of the optical element.
- the “degree of loading” of the specific binding partners on the spherical supports is understood to be the ratio of the loaded surface area, that is to say the surface area covered by the specific binding partners, of the spherical supports multiplied by a factor of 100, divided by the total surface area of the spherical supports in the monolayer or sub-monolayer. In general, this degree of loading is 10-90#.
- a similar "degree of loading" can be quoted for the ligand on the spherical supports (see definition of "leaving agent”) .
- the immobilisation of the specific binding partners or ligands on the latex spheres is a phenomenon known per se.
- a general description of the technique is given in "Micro- particle Immunoassay Techniques" (Seradyn Inc., ed. Galloway and Hicks, Particle Technology Division, P.O. Box 1210, Indianapolis, IN 46206, USA).
- the supports loaded with specific binding partners can be bound to the metal layer of the optical element by means of absorption or by means of the application of a thin layer of adhesive or sticky layer of another type via a dip technique, spin coating or other generally known deposition techniques.
- the above procedure can be carried out in reverse by first carrying out the adhesion of the spheres to the metal layer of the optical element and then the immobilisation of the specific binding partners on the spheres acting as supports.
- the supports in particle form can also be applied to the metal surface via a flat coating, such as a polystyrene coating, that is to say the supports in particle form are immobilised in an indirect manner on the metal surface.
- the sensitivity of the measuring system can be optimised using combinations of supports in particle form, antibodies and antigens. This is dependent on the application which is developed.
- the supports in particle form act as an interface between the biological domain and the optical domain.
- the light sources used can be the light sources known from the prior art, such as the helium-neon laser light source and the infrared diode laser light source.
- the invention also relates to an optical element, suitable for use in an SPR measuring apparatus and consisting of a transparent platelet or fibre made of plastic or glass, a single surface of which is coated with a metal layer of gold or silver, which metal layer is provided with an amount of support-s in particle form, applied thereon, which contain specific binding partners; details in this regard are given above.
- FIG. 3b is a diagrammatic representation of the "competition assay" in respect of the binding of a mixture of ligands and supports in particle form provided with a ligand to antibodies which are bound to the metal surface (see curves c and a of Fig. 10 for the order of size in respect of the difference in measured angle) .
- Fig. 4 diagrammatic representation of the method according to the invention, where the specific binding partner is located on supports in particle form adhering to the surface of the optical element and binds to ligands.
- Fig. 5 diagrammatic representation of the method according to the invention, in which the "leaving agent" is located on specific binding partners for the ligand adhering to the surface of the optical element and is removed by the ligand via a displacement reaction.
- Fig. 6 diagrammatic representation of the method according to the invention, in which an equilibrium setting is shown between the specific binding partners adhering to the surface of the optical element (9) and the ligand and "leaving agent" present in the medium.
- Fig. 6a(0 ⁇ 3) show time points in respect of a measurement
- Fig. 6a(0) representing the equilibrium phase at time t 0
- Fig. 6a(l) representing the sampling at time t_
- Fig. 6a(2) representing the equilibrium phase changed because of the sampling, at time t 2
- Fig. 6a(3) representing the restored equilibrium phase (as at t 0 ) at time t 3 .
- Fig. diagrammatic representation of the method according to the invention, in which a membrane (10) which is permeable to the ligand but impermeable to the "leaving agent" is fitted between the surface of the optical element (9) with the specific binding partners adhering thereto and the location at which the sample to be investigated is supplied.
- Fig. 8 diagrammatic representation of the method according to the invention, in which the specific binding partners for the ligand are present on the spheres adhering to the surface of the optical element and in which the specific binding partners for the ligand itself are provided with a "leaving agent", which "leaving agent” is removed by the ligand via a displacement reaction.
- Fig. shows an optical system which is used for generating surface plasmon resonance effects, as shown in Fig. 10. In this Fig. 9.
- (11) represents a prism, (12) an incident ray of polarised light, (13) the reflected light ray, (14) a glass substrate, (15) a gold layer applied to the substrate, (16) a layer of specific binding partners, or latex spheres loaded with specific binding partners according to the invention, applied to the gold layer and
- Fig. 10 shows a graph of the measurement results obtained using SPR (see example below) , where
- Fig. 11 represents a graph of a competition assay between a blank hCG-coated latex on the one hand (curve a) and a 250 IU hCG & hCG-coated latex mixture on the other hand (curve b) in a SPR measuring apparatus, in which assay poly- clonal anti-hCG applied to the gold layer acted as anti ⁇ body.
- Fig. 12 is a graph of a SPR measurement where represents Biocryl spheres represents; represents blank (Biocryl spheres with PCR mixture but without DNA fragments); represents Biocryl spheres with PCR mixture and DNA fragments.
- the measurement set-up shown in Fig. 9 was used in this example.
- the gold layer was first provided with a coating.
- HSA human serum albumin
- Polybead polystyrene (2.5% solids) carboxylated micro- spheres (100 nm) (Polysciences Corp., Niles/Ill. USA) were then applied to the abovementioned coated gold layer. After 10 min the metal surface was rinsed with PBS.
- the resulting product was then rinsed with a borate buffer (Polysciences Corp., Niles/Ill., USA).
- protein HSA; Sigma A 3782
- a solution containing anti-HSA (Sigma, no. A 1151) was dripped onto the coated gold layer. The product was then incubated for 1 hour. It was then rinsed with PBS. The relevant measurements were carried out with the aid of a measurement apparatus as shown in
- curve (a) shows the measurement result for HSA applied directly to the gold layer coated with polystyrene; this layer was prepared in the above manner omitting the steps involving the latex spheres. It can be seen from this figure that the sensitivity of the gold layer coated with latex spheres has been appreciably increased (c ⁇ d) compared with the uncoated gold layer (a -> b) .
- a competition mixture was used for the detection, by mixing a hCG-coated latex solution (0.01% solids concentration) with an hCG solution of variable concentration.
- the blank contains no free hCG.
- the latex and hCG were diluted in 0.1% gelatine in
- PBS/Tween 20 200 ⁇ l of solution were applied to the gold platelet.
- Biocryl spheres (Toso Haas, size 0.1 um, type Biocryl BPA 1000)
- DNA material DNA from PVA plasmid
- the aim of the experiment described in this example is to investigate whether it is possible to measure DNA using Biocryl spheres which, because of their positive charge, display a high affinity for DNA. Since Biocryl spheres in PBS buffer themselves already ensure a large angle shift in SPR experiments and DNA ad ⁇ heres to these spheres with screening of the charge of the Biocryl spheres, this DNA screening should give rise to a smaller shift in angle.
- the experiment was carried out as follows. 1 ml of PBS was placed in two Eppendorf tubes. A number of Biocryl spheres (in total 1 ⁇ l, 1.5 ⁇ l, 2.0 ⁇ l and 2.5 ⁇ l) diluted 10-fold were then added to each tube. The contents of the tubes were mixed using a vortex stirrer. A PCR mixture containing DNA (35 ⁇ l) was then added to one tube. This tube was mixed well using a vortex stirrer. Finally, the contents of both tubes were transferred to two cuvettes, after which the SPR determinations were carried out. On the basis of photographs of the gel, the DNA concentration was estimated to be 2, 3 ⁇ 4 and 6 ⁇ g/ml. The length of the DNA fragments was in the range of from 400- 2900 bp. A blank PCR mixture, that is to say the PCR mixture, but no DNA, was present, served as blank determination in this example.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91909534A EP0600862A1 (en) | 1990-05-02 | 1991-05-01 | Method for determining a specific ligand in a fluid sample with the aid of an evanescent field, and also a component of the requisite measuring equipment suitable for this purpose |
JP3509330A JPH06502717A (en) | 1990-05-02 | 1991-05-01 | Method for measuring specific ligands in fluid samples using infinitesimal fields and also essential measuring device components suitable for this purpose |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL9001052A NL9001052A (en) | 1990-05-02 | 1990-05-02 | METHOD FOR DETERMINING A SPECIFIC LIGAND IN A LIQUID SAMPLE USING AN EVANESCENT FIELD, AND AN APPROPRIATE PART OF THE MEASURING DEVICE REQUIRED. |
NL9001052 | 1990-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991017427A1 true WO1991017427A1 (en) | 1991-11-14 |
Family
ID=19857049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL1991/000073 WO1991017427A1 (en) | 1990-05-02 | 1991-05-01 | Method for determining a specific ligand in a fluid sample with the aid of an evanescent field, and also a component of the requisite measuring equipment suitable for this purpose |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0600862A1 (en) |
JP (1) | JPH06502717A (en) |
AU (1) | AU7871491A (en) |
NL (1) | NL9001052A (en) |
WO (1) | WO1991017427A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0597503A2 (en) * | 1992-11-13 | 1994-05-18 | Amgen Inc. | ECK receptor ligands |
DE4307042A1 (en) * | 1993-03-05 | 1994-09-08 | S & L Ges Fuer Wissenschaftlic | Method for the qualitative and quantitative optical detection of molecules, biomolecules and microorganisms |
WO1996036713A2 (en) * | 1995-05-19 | 1996-11-21 | Amgen Inc. | Eck receptor ligands |
USRE44693E1 (en) | 1996-11-06 | 2014-01-07 | Sequenom, Inc. | Beads bound to a solid support and to nucleic acids |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1817629A1 (en) * | 1968-01-02 | 1969-08-21 | Philips Nv | Optical element for the detection of aerosols using internal reflection |
US3979184A (en) * | 1975-05-27 | 1976-09-07 | General Electric Company | Diagnostic device for visually detecting presence of biological particles |
US4054646A (en) * | 1973-07-30 | 1977-10-18 | General Electric | Method and apparatus for detection of antibodies and antigens |
WO1988007202A1 (en) * | 1987-03-10 | 1988-09-22 | Ares-Serono Research & Development Limited Partner | Improved assay technique and apparatus therefor |
EP0326375A2 (en) * | 1988-01-27 | 1989-08-02 | Ortho Diagnostic Systems Inc. | Scattered total internal reflectance immunoassay system |
EP0341928A1 (en) * | 1988-05-10 | 1989-11-15 | AMERSHAM INTERNATIONAL plc | Improvements relating to surface plasmon resonance sensors |
EP0353937A1 (en) * | 1988-07-25 | 1990-02-07 | Applied Research Systems Ars Holding N.V. | Method of assay |
-
1990
- 1990-05-02 NL NL9001052A patent/NL9001052A/en not_active Application Discontinuation
-
1991
- 1991-05-01 EP EP91909534A patent/EP0600862A1/en not_active Withdrawn
- 1991-05-01 AU AU78714/91A patent/AU7871491A/en not_active Abandoned
- 1991-05-01 WO PCT/NL1991/000073 patent/WO1991017427A1/en not_active Application Discontinuation
- 1991-05-01 JP JP3509330A patent/JPH06502717A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1817629A1 (en) * | 1968-01-02 | 1969-08-21 | Philips Nv | Optical element for the detection of aerosols using internal reflection |
US4054646A (en) * | 1973-07-30 | 1977-10-18 | General Electric | Method and apparatus for detection of antibodies and antigens |
US3979184A (en) * | 1975-05-27 | 1976-09-07 | General Electric Company | Diagnostic device for visually detecting presence of biological particles |
WO1988007202A1 (en) * | 1987-03-10 | 1988-09-22 | Ares-Serono Research & Development Limited Partner | Improved assay technique and apparatus therefor |
EP0326375A2 (en) * | 1988-01-27 | 1989-08-02 | Ortho Diagnostic Systems Inc. | Scattered total internal reflectance immunoassay system |
EP0341928A1 (en) * | 1988-05-10 | 1989-11-15 | AMERSHAM INTERNATIONAL plc | Improvements relating to surface plasmon resonance sensors |
EP0353937A1 (en) * | 1988-07-25 | 1990-02-07 | Applied Research Systems Ars Holding N.V. | Method of assay |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0597503A2 (en) * | 1992-11-13 | 1994-05-18 | Amgen Inc. | ECK receptor ligands |
EP0597503A3 (en) * | 1992-11-13 | 1995-05-24 | Amgen Inc | ECK receptor ligands. |
US6087167A (en) * | 1992-11-13 | 2000-07-11 | Amgen Inc. | Eck receptor ligands |
US6479250B1 (en) | 1992-11-13 | 2002-11-12 | Amgen Inc. | Eck receptor ligands |
DE4307042A1 (en) * | 1993-03-05 | 1994-09-08 | S & L Ges Fuer Wissenschaftlic | Method for the qualitative and quantitative optical detection of molecules, biomolecules and microorganisms |
WO1996036713A2 (en) * | 1995-05-19 | 1996-11-21 | Amgen Inc. | Eck receptor ligands |
WO1996036713A3 (en) * | 1995-05-19 | 1997-05-29 | Amgen Inc | Eck receptor ligands |
USRE44693E1 (en) | 1996-11-06 | 2014-01-07 | Sequenom, Inc. | Beads bound to a solid support and to nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
NL9001052A (en) | 1991-12-02 |
JPH06502717A (en) | 1994-03-24 |
EP0600862A1 (en) | 1994-06-15 |
AU7871491A (en) | 1991-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0598003B1 (en) | Substrate for surface-enhanced analytical procedures, and substrates prepared for specific procedures | |
RU2025732C1 (en) | Method of analyte immunoassay in aqueous sample | |
US5837552A (en) | Surface-enhanced analytical procedures and substrates | |
US8426152B2 (en) | Enzymatic assay for LSPR | |
CA1336393C (en) | Test method and reagent kit therefor | |
US4992385A (en) | Polymer-coated optical structures and methods of making and using the same | |
CA1039632A (en) | Substrate for immunological tests and method of fabrication thereof | |
AU654262B2 (en) | Method and apparatus for detection of an analyte | |
IE61365B1 (en) | A solid phase system for use in ligand-receptor assays | |
JPS5855758A (en) | Method, means and device for measuring biological component | |
EP0564494B1 (en) | Test method and reagent kit therefor | |
JP3193373B2 (en) | Immobilized analyte detection device | |
US7129096B2 (en) | Sensor for use in testing biological, biochemical, chemical or environmental samples | |
WO1991017427A1 (en) | Method for determining a specific ligand in a fluid sample with the aid of an evanescent field, and also a component of the requisite measuring equipment suitable for this purpose | |
WO1993025910A1 (en) | Assay for multiple analytes with co-immobilized ligands | |
JP2834950B2 (en) | Sensitive optical immunoassay using enzyme labeling reagents | |
JP2001235473A (en) | Device for detecting immobilized analyte | |
Kawaguchi et al. | A highly sensitive device for visual detection of antigens and antibodies by means of light interference |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991909534 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1991909534 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991909534 Country of ref document: EP |